Compare
Krazati vs. Lumakras

Krazati (adagrasib) is a KRAS inhibitor that's FDA approved to treat advanced and metastatic non-small cell lung cancer (NSCLC) and colorectal cancer in adults with the KRAS G12C mutation. It’s typically used when previous treatments stop working. This medication is used alone to treat NSCLC. But for colorectal cancer, it's used with Erbitux (cetuximab), an infusion given once a week or every other week. Krazati (adagrasib) is conveniently available as an oral tablet which is taken by mouth twice a day. But it can commonly cause bothersome side effects such as diarrhea, nausea, and fatigue.

• Locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, after having tried at least one previous cancer treatment
• Locally advanced or metastatic colorectal cancer with a KRAS G12C mutation, together with Erbitux (cetuximab), after having tried certain previous cancer treatments

• Diarrhea (70%)
• Nausea (69%)
• Lower blood cell counts (up to 64%)
• Fatigue (59%)
• Vomiting (56%)
• Signs of stress to the liver or kidney on blood tests (up to 52%)
• Muscle or bone pain (41%)
• Liver injury (37%)
• Kidney injury (36%)
• Shortness of breath (35%)
• Swelling (32%)
• Loss of appetite (30%)

Note: Side effects noted above were reported in studies where Krazati (adagrasib) was used alone for lung cancer.

• Severe digestive system problems
• Life-threatening abnormal heart rhythm
• Liver injury
• Lung damage

Lumakras (sotorasib) is a medication that’s used for metastatic non-small cell lung cancer (NSCLC). In particular, it’s used for adults who have a specific mutation called KRAS G12C in their lung cancer. Lumakras (sotorasib) is typically recommended only when first-choice treatment doesn’t work anymore. It can be a convenient option since it’s taken by mouth once a day. But, it commonly causes bothersome side effects, like stomach upset and fatigue.

• Metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, after having tried at least one previous cancer treatment

• Diarrhea (42%)
• Muscle or bone pain (35%)
• Fatigue (26%)
• Nausea (26%)
• Cough (20%)

• Liver injury
• Lung damage